Graft-versus-host disease (GVHD) is the major obstacle for successful allogeneic stem cell transplantation (SCT). Morbidity and mortality are high, and novel therapeutic strategies are required. Current therapy, which is based mainly on immunosuppression, is associated with a high degree of complications. Immune hyporesponsiveness induced by oral antigen administration has recently been shown to prevent the development of chronic GVHD (cGVHD) in a murine model. The aim of the present study was to evaluate whether it is possible to induce tolerance and to alleviate GVHD in a semiallogeneic transplantation model in mice. GVHD was generated by infusing 2 Â 10 7 splenocytes from C57BL/6 donor mice into (C57BL/6 Â Balb/c)F1 recipient mice, which received 7 Gy 60 Co total body irradiation (TBI) prior to transplantation. Oral tolerance was induced by feeding recipient F1 mice with five oral doses of proteins, 50 lg/mouse, extracted from C57BL/6 splenocytes on alternate days following transplantation. In vitro mixed lymphocyte reaction (MLR) from tolerized and nontolerized mice was performed. Recipient mice were followed for chimerism, and for clinical and histological parameters of GVHD. Induction of tolerance was documented by a significant reduction in MLR response of tolerated vs nontolerated splenocytes. A significant alleviation of the clinical and pathological manifestation of GVHD was observed in the liver, small bowel, and skin. Tolerance induction did not jeopardize engraftment. These results may constitute a step towards reducing the frequency of GVHD via manipulation of the immune system.
Graft-versus-host disease (GVHD) is a multi-organ disorder that develops following stem cell transplantation (SCT). 1 The pathogenesis involves recognition of alloreactive antigens, activation of T cells, as well as other immunocompetent effector cells, and tissue destruction. 2 Oral tolerance has been shown to be effective in various experimental models of immune mediated disorders. 3 Feeding small doses of the antigen has been reported to induce tolerance by generation of negative immunoregulatory cells, while administering higher doses tends to bring about clonal inactivation or deletion. 4 We have previously shown that induction of oral tolerance towards recipient splenocytes in bone marrow transplant donors, prior to bone marrow transplantation (BMT), can prevent the development of graft-versus-host inflammatory immune response. 5 We used the mouse model of chronic GVHD (cGVHD), which involved transplantation of B10.D2 splenocytes into sublethally irradiated BALB/c mice. These mouse strains are identical at MHC gene (H-2 d ) loci, but differ by their multiple minor histocompatibility antigens. Intravenous infusion of splenocytes from B10.D2 into BALB/c mice, induces cGVHD manifested by scleroderma-like skin lesions, an increase in skin collagen, thickening of the dermis, and a loss of subdermal fat. Liver and gastrointestinal tract injuries in this model include inflammatory destruction of intrahepatic bile ducts and the bowel mucosa. 6, 7 Feeding donor mice homogenates of recipient splenocytes before transplantation prevented the clinical and microscopic manifestations of cGVHD. 5 In addition, using the same cGVHD model, we have recently shown the possibility of inducing tolerance in recipients towards their pre transplant antigens. 8 Transplantation resulted in cGVHD with characteristic scleroderma-like cutaneous fibrosis, increased skin collagen content, and decreased body weight, along with hepatic and small bowel inflammation. Oral tolerance was induced by feeding recipient BALB/c mice with proteins extracted from BALB/c splenocytes following B10.D2 splenocyte transplantation. Tolerance induction was evidenced by a significant reduction in mixed lymphocyte response of effector splenocytes from tolerized BALB/c mice transplanted with B10.D2 splenocytes against BALB/c target splenocytes. Oral tolerization decreased skin collagen deposits. Reduction of collagen a1(I) gene expression and skin collagen were shown by in situ hybridization and histochemistry, respectively. Liver and bowel biopsies revealed less inflammation.
Acute GVHD is the major complication post-allogeneic SCT, including modern types of transplant, namely, transplantation post-low-intensity condition or nonmyeloablative regimens. Clinical application of this method, however, will require tolerance induction across major histocompatibility antigens. The aim of the present study was to determine whether induction of oral tolerance toward recipient splenocytes, following transplantation, alleviates GVHD in semiallogeneic C57BL/6 to (C57BL/ 6 Â Balb/c)F1 mice model. The results show that tolerance induction significantly alleviated GVHD, as manifested by suppression of in vitro alloreactivity, improved survival, reduced lymphocytic infiltration, and other typical histopathological GVHD manifestations in the target organs.
Materials and methods

Animals
Donor mice were 12-week-old C57BL/6 males, obtained from Jackson Laboratories (Anne Harbor, ME, USA). Recipients were (C57BL/6 Â Balb/c)F1 female mice. The mice were kept in 12 h light/dark cycles in the Animal Core of the Hadassah-Hebrew University Medical School. All animals were fed regular laboratory chow and imbibed water ad libitum. All animal experiments were approved by the Hebrew-University-Hadassah Institutional Committee for the Care and Use of Laboratory Animals. Following irradiation and splenocyte transplantation, the mice were maintained in laminar flow isolators.
Splenocyte transplantation
To induce GVHD, 2 Â 10 7 spleen cells from C57BL/6 donor mice were injected intravenously into (C57BL/ 6 Â Balb/c)F1 recipient mice. Mice were given 60 Co whole-body irradiation (7 Gy) prior to transplantation.
Preparation and administration of proteins to recipients
Following excision of spleens from recipient mice, splenocytes were mechanically homogenized under a 60 mesh stainless-steel strainer. Cells were treated with red blood cell lysis buffer to eliminate erythrocytes, and washed three times with phosphate-buffered saline (PBS). Proteins were measured using the Biorad Protein assay reagent. Recipient mice were fed homogenates containing 50 mg of proteins using atraumatic cannulae every other day, for a total of five doses. The dose of splenocytes used was determined by initial dosing experiments performed by others as well as ourselves.
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Experimental groups
Four groups of recipient F1 mice, consisting of 10 animals each, were studied. Mice in all groups were transplanted with C57BL/6 splenocytes as described above. Recipient mice in experimental group A were fed homogenates of splenocytes derived from recipient strain F1 mice. Recipient mice in control groups B, C, and D were fed homogenates prepared from Balb/c, C57BL/6 splenocytes, or bovine serum albumin (BSA), respectively. Mice in all groups were fed five doses every other day, beginning 7 days following splenocyte transplantation.
Evaluation of tolerance induction in recipient mice and assessment of recipient's response towards recipient or donor cells by one-way mixed lymphocyte reaction assay Tolerance induction in recipient F1 mice towards semiallogeneic histocompatibility antigens of parental strain mice (C57BL/6, Balb/c) was evaluated by one-way mixed lymphocyte reaction (MLR) tests. MLR tests were performed in five animals from groups A and D, 53 days following transplantation. Splenocytes (1 Â 10 6 ) from groups A and D separately were cultured in flat-bottom microwell plates (Sterilin cat. no. M29ARTL), with irradiated (30 Gy) effector spleen cells (2 Â 10 6 ) derived from naı¨ve F1, C57BL/6, or Balb/c, in a total volume of 0.2 ml RPMI 1640 culture medium, supplemented with 100 mg/ml penicillin, 100 mg/ml streptomycin, 2 mM l-glutamine, with 5 Â 10 À5 M 2ME, and 10% FCS. After 72 h in a 371C humidified 5% CO 2 incubator, 1 mmCi of 3H TdR (5 Ci/nmol, Nuclear Research Center, Negev, Israel) was added to each well. Cells were collected 16-18 h later on paper filters, using a multiple sample harvester (Titertek Cell Harvester 530; Flow Laboratories. McClean, VA 22102). Radioactivity was measured by a liquid scintillation counter. In both tests, background results from tolerated and nontolerated F1 splenocytes against themselves were subtracted.
Chimerism
Per cent of chimerism was evaluated by FACS analysis using anti Balb/c antibodies as previously described. 12 Per cent of chimerism was analyzed in recipient groups A and D, fed with F1 and BSA, respectively.
Assessment of GVHD
GVHD assessment was performed 53 days after transplantation using the following parameters: total body weight, general appearance, survival, and histology of skin, bowel, and liver.
Body weight
Body weight was recorded every week for each animal in experimental and control groups throughout the study.
Grading of histologic changes of GVHD
All mice from all groups were killed at 53 days following splenocyte transplantation. For evaluation of the degree of dermal, hepatic, and intestinal inflammation, tissues were removed from all mice in both groups and kept in 10% formaldehyde. Five tissue sections from each mouse were embedded in paraffin, sectioned, and stained with hematoxylin-eosin by standard procedure. The degree of inflammation of coded microscopic sections of liver and small bowel were graded semiquantitatively from 0 to 4, as Oral tolerance and acute GVHD A Nagler et al previously described, by two experienced pathologists who were unaware of the experimental conditions. Liver sections were graded according to standard scoring criteria as described. 6, 13, 14 In brief, Grade 0: normal or less than 30% portal infiltration (based on the percentage of portal tracts expanded by inflammatory cells) and normal bile duct epithelium; Grade 1: 30-40% portal inflammation, and normal bile duct epithelium; Grade 2: 40-60% portal inflammation, and abnormal bile duct epithelial morphology; Grade 3: 60-80% portal inflammation and lymphocyte infiltration of bile ducts; and Grade 4: 80-100% portal inflammation, and death of bile duct cells or disruption of bile ducts. Small bowel specimens were graded by the following scale: Grade 0: normal intestinal mucosa; Grade 1: mild distortion of villous architecture with a normal amount of mucous cells, an occasional apoptotic cell in base of crypts with evidence of cryptic hyperplasia; Grade 2: partial effacement or blunting of the villous architecture, mucous cell depletion, sloughing of epithelial cells within the lumen, marked apoptosis and crypt hyperplasia, and mononuclear cell infiltration within lamina propria and cryptitis; Grade 3: as in grade 2, plus patchy or total mucosal necrosis or ulceration. [14] [15] [16] Skin biopsies were graded according to Lerner criteria based on frequency of epidermal atrophy, spongiosis, diffuse basal vacuolization, more than three single necrotic keratinocytes per highpower field, satellitosis, inflammatory infiltrate, with a predominantly lichenoid pattern, lymphocytic exocytosis, and dermal melanophages. 15 
Statistical analysis
Results were analyzed by two tailed Student's t-test.
Results
The effect of oral tolerization in recipient mice towards recipient or donor cells by one-way MLR assay Tolerance induction in recipient F1 mice towards semiallogeneic histocompatibility antigens of recipient or parental strain mice (C57BL/6, Balb/c) was evaluated by one-way MLR tests. Lymphocytes extracted from mice in group A and fed with F1-extracted proteins showed reduced alloreactivity towards F1, C57BL/6, or Balb/c stimulating cells (2236, 1264, and 1509 cpm, respectively). In contrast, lymphocytes harvested from control group D and fed with BSA showed a significant increase in the alloreactivity towards F1 (5322 cpm) and a modest increase in reactivity towards Balb/c (2716 cpm). Low counts were observed when C57BL/6 cells were used as stimulator cells (2135 cpm, Figure 1 ).
Chimerism
Per cent of chimerism was analyzed in groups A and D recipient mice. Mice in group A, fed with F1-extracted proteins, demonstrated 66.3% chimerism (stained for antiBalb/c), similar to the control mice from group D, fed with BSA which showed 45.7% (P ¼ NS).
Effect of oral tolerization of BMT recipients on GVHD manifestations
Body weights. Whole-body weights were followed for mice from all the four experimental groups and with no significant difference evidenced among the groups during and at the end of the study (53 days). No significant differences in mean body weight gain were noted between the experimental and control groups. Mice in group A lost 17% of initial body weight, while mice in groups B, C and D lost 15, 21, and 22%, respectively (P ¼ NS).
Survival. Oral tolerization towards recipient antigens led to a significant increase in survival following SCT. Mice in group A, fed with F1-extracted proteins, demonstrated 88% survival. In contrast, almost all mice in group D, fed with BSA, died by day 26 of the study (10% survival, Po0.005). Mice in groups B and C, fed with Balb/c, or C57BL/6-extracted proteins, showed 50 and 30% survival, respectively (Figure 2) .
Alleviation of GVHD of the skin by oral tolerization. Skin biopsies were performed in all mice from all experimental and control groups 53 days following transplantation (Figure 3d, g, j, m) , and from normal F1 controls (Figure 3a) . No significant deviations from normal histology were identified in group A mice (Figure 3d ). In group B mice, the epidermis showed diffuse vacuolization Oral tolerance and acute GVHD A Nagler et al of the basal cell layer, spongiosis and dyskeratotic keratinocytes and subepidermal cleft formation, morphological changes characterizing grade II of acute GVHD (Figure 3g ). In contrast, in group C mice, subepidermal cleft formation with focal complete loss of the epidermis was observed, compatible with grade III-IV of acute GVHD (Figure 3j ). In group D mice, ulcer formation with complete loss of the epidermis and acute and chronic inflammation in the dermis were noticed, compatible with grade IV of acute GVHD (Figure 3m ).
Alleviation of GVHD of small bowel by oral tolerization.
Small bowel biopsies were performed in all mice from all experimental and control groups 53 days following transplantation (Figure 3e , h, k, n), and from normal F1 controls (Figure 3b ). Significant alleviation of all parameters was observed in mice from experimental group A fed with homogenates of splenocytes derived from F1 strain mice. Individual crypts were affected, showing apoptotic bodies (single-cell necrosis), characteristic of grade I of acute GVHD (Figure 3e ). In group B mice, apoptotic bodies (single-cell necrosis) were found in many crypts, the changes being characteristic of grade I acute GVHD but more extensive, as compared to those seen in group A (Figure 3h ). In group C mice, changes including apoptosis as seen in previous groups were seen, accompanied by necrotic debris in crypts resembling crypt abscesses, changes compatible with grade II acute GVHD (Figure 3k ). In group D mice, grade II changes of acute GVHD, characterized by the same histological changes as seen in group C, were observed (Figure 3n ).
Amelioration of GVHD-associated liver disease by oral tolerization. Liver biopsies were performed on all splenocyte recipients from all groups 53 days following transplantation (Figure 3f , i, l, o), as well as from normal F1 controls (Figure 3c ). Mice in experimental group A, fed with homogenates of splenocytes derived from recipient F1 mice, showed mild degrees of portal inflammation, lymphocyte infiltration and/or disruption of intrahepatic bile ducts, mild non-suppurative cholangitis with intraepithelial lymphocytes, and damaged biliary epithelium (Figure 3f ). In group B mice, fed with Balb/c-extracted proteins, and in group C mice, fed with C57BL/6-extracted proteins, similar histological changes were noted (Figure 3i and l, respectively). In contrast, group D mice, fed with BSA, evidenced severe nonsuppurative cholangitis, accompanied by endothelialitis characterized by damage to the venous endothelium (lymphocytic infiltration and sloughing, Figure 3o ).
Discussion
GVHD accounts for much of the morbidity and mortality associated with allogeneic BMT. The results of the present study show that oral administration of low doses of splenocyte homogenates of the recipient strain following transplantation, induces tolerance and ameliorates GVHD manifestations in a semiallogeneic mouse model. Oral tolerance is a recognized procedure for induction of antigen-specific peripheral immune hyporesponsiveness. 3, 4 We have previously shown in a minor histocompatibility cGVHD mouse model that oral administration of low doses of splenocyte homogenates of recipient strain to donors, prior to splenocyte transplantation, induces tolerance toward recipient alloantigens. Tolerance was documented by a significant reduction in MLR response of donor lymphocytes toward recipient splenocytes, and by prevention of the inflammatory immune response, which in turn resulted in the prevention of skin, small bowel, and liver manifestations of cGVHD. 5 However, clinical application of this method would require inducing tolerance in the presence of pre-existing disease, as well as immunomodulating the recipient, rather than the donor. Subsequently, we used a similar strategy in a cGVHD model, in which Balb/C mice were fed with Balb/C splenocyte homogenate following B10D2 into Balb/C transplantation. In this chronic GVHD model, we were able to demonstrate significant attenuation of the end organ GVHD injury in skin, gut, and liver. 8 GVHD across major, or semiallogeneic barrier (acute GVHD), is a frequent (40-70%) complication postallogeneic SCT, in which alloreactive T cells are the key players. 2 Thus, it was of importance to demonstrate that oral tolerance induction may be applicable for GVHD in a semiallogeneic SCT.
The results of the present study show that induction of oral tolerance post transplantation, in the C57BL/6 into F1 mouse model, downregulated the inflammatory response, thus ameliorating GHVD. The ability to induce immune tolerance was demonstrated in vitro using the MLR assay in which lymphocytes harvested from mice, fed with F1-extracted proteins, showed reduced alloreactivity. In Oral tolerance and acute GVHD A Nagler et al contrast, lymphocytes harvested from control mice, fed with BSA, showed normal alloreactivity. Clinical amelioration of GVHD was documented by a significant improvement in the skin, bowel, and liver pathology in the tolerized mice in comparison with controls. Skin biopsies from tolerized mice demonstrated significant alleviation of the morphological changes characterizing acute GVHD. In contrast, nontolerized control mice showed the typical GVHD insult, including diffuse vacuolization of the basal cell layer, spongiosis and dyskeratotic keratinocytes, and subepidermal cleft formation. Similarly, small bowel biopsies of tolerized mice showed almost normal morphology, while control mice showed apoptotic bodies, single-cell necrosis, and necrotic debris in crypts resembling crypt abscesses. Finally, liver biopsies from tolerized mice showed only a mild degree of portal inflammation. In contrast, control mice showed severe nonsuppurative cholangitis accompanied by endothelialitis characterized by damage to the venous endothelium. The attenuation of clinical and pathological manifestations of GVHD by oral Figure 3 Alleviation of GVHD of the skin, small bowel, and liver by oral tolerization. Skin biopsies were performed in all mice from all experimental and control groups, and from normal F1 controls (a). No significant deviations from normal histology were identified in group A mice (d). In group B mice, the epidermis showed diffuse vacuolization of the basal cell layer, spongiosis and dyskeratotic keratinocytes and subepidermal cleft formation, morphological changes characterizing grade II acute GVHD (g). In contrast, group C mice exhibited subepidermal cleft formation with focal complete loss of the epidermis, compatible with grade III-IV acute GVHD (j). In group D mice, changes included ulcer formation with complete loss of the epidermis and acute and chronic inflammation in the dermis, compatible with grade IV acute GVHD (m). Small bowel biopsies were normal for normal F1 controls (b). Significant alleviation of all parameters was observed in mice from experimental group A fed with homogenates of splenocytes derived from F1 strain mice. Individual crypts were affected, showing apoptotic bodies (single-cell necrosis), characteristic of grade I acute GVHD (e). In group B mice, apoptotic bodies (single-cell necrosis) were found in many crypts, changes being characteristic of grade I acute GVHD, but more extensive compared with those seen in group A (h). In group C mice, apoptosis as in previous groups was seen, accompanied by necrotic debris in crypts resembling crypt abscesses, changes compatible with grade II acute GVHD (k). Group D mice exhibited grade II changes of acute GVHD, characterized by the same histological changes as seen in group C (n). Liver biopsies were performed on normal F1 controls (c). Mice in experimental group A, fed with homogenates of splenocytes derived from recipient F1 mice, showed mild degrees of portal inflammation, lymphocyte infiltration, and/or disruption of intrahepatic bile ducts, with mild nonsuppurative cholangitis with intraepithelial lymphocytes and damaged biliary epithelium (f). In group B mice, fed with Balb/c-extracted proteins (i), and mice in group C, fed with C57BL/6-extracted proteins (l), similar histological changes were noted. In contrast, group D mice, fed with BSA, showed severe nonsuppurative cholangitis, accompanied by endothelialitis characterized by damage to the venous endothelium (lymphocytic infiltration and sloughing (o)).
tolerance was translated into a significant improvement in survival. Tolerized mice demonstrated 90% survival, compared with 10% in the controls. Oral tolerance was shown to be effective in several animal models of immune-mediated disorders. 4, [17] [18] [19] The immunological events leading to gut and liver injury in GVHD are T-cell mediated, somewhat similar to those shown in inflammatory bowel disease. We and others have recently shown that oral tolerance induction significantly attenuated the immune injury in an animal model of experimental colitis, with a Th1 to a Th2 immunological shift. 9, 20, 21 Cytokine dysregulation has been suggested to play a significant role both in inflammatory bowel disease and in GVHD. [22] [23] [24] [25] [26] The cytokine cascade results in amplification of local tissue injury and further promotes the inflammatory response via induction of cytotoxic T cells (CTL) and natural killer (NK) cell responses.
There is currently no effective treatment for GVHD. Efforts to control GVHD have been directed against alloreactive T cells. Glucocorticoids, FK506, cyclosporin A, and mofetyl microphenolate, ameliorate GVHD by immunosuppressive mechanisms. 27 Depleting the graft of T cells by a variety of techniques reduces GVHD by limiting the number of alloreactive cells in the infused graft. 28 However, pharmacological therapies and T cell depletion are insufficient to control GVHD, and are associated with severe side effects and toxicity, with high rates of mortality due to fulminant infections resulting from the generalized immunosuppression. These may also decrease the rate of GVL. Prevention of GVHD was also attempted through interruption of the cytokine-induced damage by administration of cytokines antagonists and blocking agents. 24 These measures, however, were either ineffective or toxic, limiting their potential application in clinical situations. In contrast, induction of oral tolerance may facilitate the surmounting of these difficulties, thus leading to an antigen-specific tolerance, while at the same time sparing the immune system.
In conclusion, using the murine semiallogeneic GVHD model, we have demonstrated that oral tolerization of recipients toward their pre transplant proteins following transplantation has downregulated the immune attack by donor effector cells on host target tissue, thus alleviating the skin, liver, and small intestine manifestations of GVHD, thereby resulting in reduced mortality. Our results, demonstrating the possibility of ameliorating GVHD by induction of oral tolerance, may be of therapeutic clinical significance.
